Market Closed -
OTC Markets
03:59:30 2024-04-19 pm EDT
5-day change
1st Jan Change
0.256
USD
-5.08%
-13.66%
-22.42%
Sales 2021
2M
Sales 2022
1.73M
Capitalization
15.89M
Net income 2021
-20M
Net income 2022
-16M
EV / Sales 2021
16.4
x
Net Debt
2021
14.51M
Net Debt
2022
20.53M
EV / Sales 2022
21.1
x P/E ratio 2021
-0.68
x
P/E ratio 2022
-0.81
x
Employees
-
Yield 2021 *
-
Yield 2022
-
Free-Float
98.82%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Pressure BioSciences, Inc. Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing
Feb. 15
CI
Transcript : CBH International LLC, Pressure BioSciences, Inc. - M&A Call
Feb. 05
Pressure BioSciences, Inc. completed the acquisition of CBH International LLC.
Jan. 21
CI
Pressure BioSciences, Inc. Receives Open Order Agreement from West Coast Manufacturing Partner
Jan. 18
CI
Pressure BioSciences, Inc. entered into a definitive agreement to acquire CBH International LLC.
Jan. 10
CI
Pressure BioSciences' BaroFold Platform Expected to Revolutionize Biopharmaceutical Production with Help from New Computational (AI/ML) Technologies
Jan. 04
CI
Pressure BioSciences, Inc. Announces the Publication of Pivotal Scientific Study in the Critical Field of Food Safety
Dec. 12
CI
Pressure BioSciences and Veterans Service Team Launch UltraShear Best-in-Class Nano-CBD Topical Spray - MMA Champ Cat Zingano Now Official VST Ambassador
Dec. 01
CI
Transcript : Pressure BioSciences, Inc., Q3 2023 Earnings Call, Nov 21, 2023
Nov. 21
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Reports Q3 Revenue $413,009
Nov. 21
MT
Pressure BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 20
CI
Pressure Biosciences Announces Exclusive Distribution Agreement with Bioscreen Instruments Pvt Ltd
23-10-18
CI
Pressure BioSciences' Partner Veterans Service Team Increases Existing Purchase Order by 10X for Bottles of UltraShear Nano-CBD Topical Spray, Effective Immediately
23-09-22
CI
Transcript : Pressure BioSciences, Inc., Q2 2023 Earnings Call, Aug 22, 2023
23-08-22
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Posts Q2 Revenue $511,800
23-08-22
MT
More news
Uncle Bud’s Health and Wellness to Expand New Premium Collection with Novel Products for Sleep, Memory, Pain, Immunity, Feminine Hygiene, and Sexual Wellness
Apr. 11
AQ
Pressure BioSciences’ Uncle Bud’s Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection”
Apr. 02
AQ
Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc.
Feb. 26
AQ
Breaking: Top OTC Stocks Making Headlines This Week! HNRC, SNNC, HALB, GEVI, PBIO
Feb. 19
AQ
Pressure BioSciences Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing
Feb. 15
AQ
More press releases
1 day -5.08%
1 week -13.66%
Current month +46.12%
1 month +78.27%
3 months -39.03%
6 months -39.05%
Current year -22.42%
More quotes
Managers
Title Age Since
Chief Executive Officer
73
78-07-31
Chief Tech/Sci/R&D Officer
70
06-04-23
Chief Tech/Sci/R&D Officer
59
06-04-02
Members of the board
Title Age Since
Chief Executive Officer
73
78-07-31
Director/Board Member
75
12-07-02
Director/Board Member
71
13-02-07
More insiders
Date
Price
Change
Volume
24-04-19
0.256
-5.08%
28 800
24-04-18
0.2697
0.00%
37,260
24-04-17
0.2697
+7.88%
20,107
24-04-16
0.25
+0.12%
43,225
24-04-15
0.2497
-15.78%
47,845
Delayed Quote
OTC Markets, April 19, 2024 at 03:59 pm EDT
More quotes
Pressure BioSciences, Inc. is engaged in providing broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. The Company's enabling platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. The Company's BaroFold technology platform allows it to enter the bio-pharma contract services and GMP manufacturing equipment sector. It has also developed the scalable and pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be preserved using existing non-thermal technologies.
More about the company
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1